Satellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy

Satellos Bioscience Inc., a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, recently announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to SAT-3247 for the potential treatment of Duchenne muscular dystrophy (“Duchenne” or “DMD”) after receiving Orphan Drug Designation earlier this year. SAT-3247 is a first-in-class oral small molecule therapeutic designed to restore the innate muscle regeneration and repair process, independent of dystrophin and regardless of exon mutation status.

Satellos Bioscience is an alumnus of the CAAP® program and presented at the OBIO® Investment Summit.